Cigna Group Quarterly Report for Q1 Ended Mar 31, 2026

Summary

Cigna Group reported strong financial results for the first quarter of 2026, with total revenues reaching $68.5 billion, a 5% increase year-over-year, driven primarily by an 11% rise in Pharmacy revenues and a 14% increase in Fees and other revenues. Shareholders' net income saw a significant jump of 25% to $1.65 billion, or $6.26 per diluted share, reflecting improved operational performance across its segments. The Evernorth Health Services segment demonstrated robust growth, with adjusted revenues up 9%, propelled by strong performance in Pharmacy Benefit Services. The Cigna Healthcare segment, despite a 21% decline in adjusted revenues primarily due to the prior year's HCSC transaction, achieved an impressive 18% increase in pre-tax adjusted income from operations, signaling margin expansion. Overall, the company's strategic focus on its health services capabilities appears to be yielding positive results, with solid revenue growth and a substantial increase in profitability.

Key Highlights

• 1Total revenues increased by 5% to $68.5 billion in Q1 2026, compared to $65.5 billion in Q1 2025.
• 2Shareholders' net income grew by 25% to $1.65 billion, translating to a diluted EPS of $6.26, up from $4.85 in the prior year.
• 3Evernorth Health Services saw adjusted revenues increase by 9% to $58.4 billion, driven by Pharmacy Benefit Services.
• 4Cigna Healthcare's pre-tax adjusted income from operations rose by 18% to $1.51 billion, despite a 21% decrease in adjusted revenues due to the HCSC transaction.
• 5Pharmacy revenues increased by 11% to $54.0 billion, indicating strong performance in this core area.
• 6Selling, general and administrative expenses decreased by 12% to $3.7 billion, partly due to the HCSC transaction, showcasing cost management efforts.
• 7The company maintained a strong liquidity position with $7.3 billion in cash and short-term investments as of March 31, 2026.

Frequently Asked Questions